AVBP Stock Overview
Operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
ArriVent BioPharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$24.41 |
| 52 Week High | US$36.37 |
| 52 Week Low | US$14.35 |
| Beta | 0 |
| 1 Month Change | -5.24% |
| 3 Month Change | -16.29% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 22.05% |
Recent News & Updates
We're Not Very Worried About ArriVent BioPharma's (NASDAQ:AVBP) Cash Burn Rate
Jan 11
We Think ArriVent BioPharma (NASDAQ:AVBP) Can Afford To Drive Business Growth
Sep 24ArriVent BioPharma: Bringing A Novel Cancer Drug From China
Sep 17Recent updates
We're Not Very Worried About ArriVent BioPharma's (NASDAQ:AVBP) Cash Burn Rate
Jan 11We Think ArriVent BioPharma (NASDAQ:AVBP) Can Afford To Drive Business Growth
Sep 24ArriVent BioPharma: Bringing A Novel Cancer Drug From China
Sep 17ArriVent Wows Investors With Promising China-Developed Lung Cancer Treatment
Jan 29Shareholder Returns
| AVBP | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -1.9% | -2.6% | 0.6% |
| 1Y | n/a | -6.9% | 24.5% |
Return vs Industry: Insufficient data to determine how AVBP performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how AVBP performed against the US Market.
Price Volatility
| AVBP volatility | |
|---|---|
| AVBP Average Weekly Movement | 7.6% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 18.8% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: AVBP has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: AVBP's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | 40 | Bing Yao | www.arrivent.com |
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002.
ArriVent BioPharma, Inc. Fundamentals Summary
| AVBP fundamental statistics | |
|---|---|
| Market cap | US$824.91m |
| Earnings (TTM) | -US$81.05m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-10.1x
P/E RatioIs AVBP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AVBP income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$81.05m |
| Earnings | -US$81.05m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.41 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did AVBP perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/17 00:29 |
| End of Day Share Price | 2025/01/17 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ArriVent BioPharma, Inc. is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yigal Nochomovitz | Citigroup Inc |
| Corinne Johnson | Goldman Sachs |
| Robert Burns | H.C. Wainwright & Co. |